PMID- 20142024
OWN - NLM
STAT- MEDLINE
DCOM- 20100907
LR  - 20181201
IS  - 1532-8414 (Electronic)
IS  - 1071-9164 (Linking)
VI  - 16
IP  - 2
DP  - 2010 Feb
TI  - Baseline plasma NT-proBNP and clinical characteristics: results from the 
      irbesartan in heart failure with preserved ejection fraction trial.
PG  - 128-34
LID - 10.1016/j.cardfail.2009.09.007 [doi]
AB  - BACKGROUND: N-terminal B type natriuretic peptide (NT-proBNP) is usually elevated 
      in heart failure (HF) patients with reduced ejection fraction (EF). Less is known 
      about NT-proBNP in HF with preserved EF (HF-PEF). We measured baseline NT-proBNP 
      in 3562 HF-PEF enrolled patients in the Irbesartan in Heart Failure with 
      Preserved Ejection Fraction trial. METHODS AND RESULTS: Patients with EF >or=45%, 
      age >or=60 years, and either New York Heart Association (NYHA) II-IV symptoms 
      with HF hospitalization (HFH) within 6 months or NYHA III-IV symptoms with 
      corroborative evidence of HF or structural changes associated with HF-PEF. 
      NT-proBNP (pg/mL) measured centrally using the Elecsys proBNP assay (Roche). Mean 
      age 72 +/- 7 years, 60% were women, the investigator indicated HF etiology was 
      hypertension in 64%; the majority were in NYHA III. Medications included 
      diuretics in 82%, angiotensin-converting enzyme inhibitor in 26%, beta-blocker in 
      59%, and spironolactone in 15%. Median NT-proBNP was 341 pg/mL (interquartile 
      range 135 to 974 pg/mL) and geometric mean was 354 pg/mL. In multivariate 
      analysis, the baseline characteristics most strongly associated with higher 
      NT-proBNP levels were atrial fibrillation (ratio of geometric mean 2.59, P < 
      .001), NYHA IV symptoms (1.52, P < .001), lower estimated glomerular filtration 
      rate (1.44, P < .001), and HFH hospitalization within 6 months (1.37, P < .001). 
      CONCLUSIONS: Most HF-PEF patients have elevated NT-proBNP levels. The NT-proBNP 
      concentrations were related to baseline characteristics generally associated with 
      worse outcomes for HF patients.
CI  - Copyright 2010. Published by Elsevier Inc.
FAU - McKelvie, Robert S
AU  - McKelvie RS
AD  - McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada. 
      robert.mckelvie@phri.ca
FAU - Komajda, Michel
AU  - Komajda M
FAU - McMurray, John
AU  - McMurray J
FAU - Zile, Michael
AU  - Zile M
FAU - Ptaszynska, Agata
AU  - Ptaszynska A
FAU - Donovan, Mark
AU  - Donovan M
FAU - Carson, Peter
AU  - Carson P
FAU - Massie, Barry M
AU  - Massie BM
CN  - I-Preserve Investigators
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20091104
PL  - United States
TA  - J Card Fail
JT  - Journal of cardiac failure
JID - 9442138
RN  - 0 (Biomarkers)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Peptide Fragments)
RN  - 0 (Protein Precursors)
RN  - 0 (Tetrazoles)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - J0E2756Z7N (Irbesartan)
SB  - IM
MH  - Aged
MH  - Biomarkers/blood
MH  - Biphenyl Compounds/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Heart Failure/*blood/*drug therapy/physiopathology
MH  - Humans
MH  - Internationality
MH  - Irbesartan
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/biosynthesis/*blood
MH  - Peptide Fragments/biosynthesis/*blood
MH  - Protein Precursors/biosynthesis/*blood
MH  - Stroke Volume/drug effects/*physiology
MH  - Tetrazoles/*therapeutic use
EDAT- 2010/02/10 06:00
MHDA- 2010/09/08 06:00
CRDT- 2010/02/10 06:00
PHST- 2008/08/28 00:00 [received]
PHST- 2009/07/27 00:00 [revised]
PHST- 2009/09/24 00:00 [accepted]
PHST- 2010/02/10 06:00 [entrez]
PHST- 2010/02/10 06:00 [pubmed]
PHST- 2010/09/08 06:00 [medline]
AID - S1071-9164(09)01091-4 [pii]
AID - 10.1016/j.cardfail.2009.09.007 [doi]
PST - ppublish
SO  - J Card Fail. 2010 Feb;16(2):128-34. doi: 10.1016/j.cardfail.2009.09.007. Epub 
      2009 Nov 4.